This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?

Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for inflammatory diseases using proprietary Nanobody technology [6] - The company targets significant unmet medical needs in dermatology and rheumatology, with a focused pipeline and ongoing clinical trials [6] Financial Performance - As of February 17, 2026, MoonLake's stock price was $17.52, reflecting a nearly 60% decline over the past year, underperforming the S&P 500's approximately 19% gain during the same period [8] - The company reported a net income of -$227.3 million (TTM) and had fourth-quarter R&D expenses of $56 million, along with administrative expenses of $9.2 million [4][11] - MoonLake ended the year with approximately $394 million in cash and equivalents, sufficient to fund operations into the second half of the following year [11] Recent Developments - Cormorant Asset Management increased its stake in MoonLake by 2,361,260 shares during the fourth quarter, with an estimated transaction value of $27.86 million [2] - The quarter-end value of Cormorant's position in MoonLake increased by $43.11 million, factoring in both additional shares and changes in share price [2] - The stock experienced a significant drop of nearly 90% in September 2025 due to mixed Phase 3 results for its investigational nanobody, sonelokimab, but Cormorant's investment suggests confidence in the company's ongoing clinical development [7][11] Product Pipeline - MoonLake's lead drug candidate, sonelokimab, is an investigational Nanobody therapy targeting inflammatory diseases, with early clinical data showing encouraging activity [9][10] - Recent trial results in axial spondyloarthritis have added another potential indication for the therapy, which could compete in large and rapidly expanding immunology markets if later-stage studies confirm these findings [10]